转移性-话题@MedSci

#转移性#

975篇内容 | 3535人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1386676, encodeId=707413866e6f3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA即将批准液体活检技术Parsortix用于转移性乳腺癌, objectType=article, longId=202390, objectId=03fb202390a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fb202390a6, replyNumber=0, likeNumber=56, createdTime=2020-10-24, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fb202390a6, moduleTitle=FDA即将批准液体活检技术Parsortix用于转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03fb202390a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386675, encodeId=c04813866e510, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗, objectType=article, longId=202368, objectId=85c8202368f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85c8202368f2, replyNumber=0, likeNumber=58, createdTime=2020-10-23, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85c8202368f2, moduleTitle=Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85c8202368f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386674, encodeId=546313866e475, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Br J Cancer：FOLFOXIRI和贝伐单抗治疗转移性结直肠癌的临床研究汇总分析, objectType=article, longId=202252, objectId=88af2022522e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88af2022522e, replyNumber=0, likeNumber=81, createdTime=2020-10-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88af2022522e, moduleTitle=Br J Cancer：FOLFOXIRI和贝伐单抗治疗转移性结直肠癌的临床研究汇总分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88af2022522e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386673, encodeId=c2c713866e31e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Br J Cancer：错配修复不足的转移性结直肠癌dMMR mCRC患者的生存分析, objectType=article, longId=202147, objectId=30ba20214e5d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30ba20214e5d, replyNumber=0, likeNumber=86, createdTime=2020-10-17, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30ba20214e5d, moduleTitle=Br J Cancer：错配修复不足的转移性结直肠癌dMMR mCRC患者的生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30ba20214e5d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386672, encodeId=333313866e22d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JAMA Oncol ：咖啡又一功效！可改善结直肠癌晚期或转移性患者的生存率和恶化风险, objectType=article, longId=202110, objectId=cfcc20211089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfcc20211089, replyNumber=0, likeNumber=95, createdTime=2020-10-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfcc20211089, moduleTitle=JAMA Oncol ：咖啡又一功效！可改善结直肠癌晚期或转移性患者的生存率和恶化风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfcc20211089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386671, encodeId=70d913866e15e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Sci Rep：肌肉浸润性或转移性膀胱癌患者化疗的模式和临床结果, objectType=article, longId=201988, objectId=db4a20198860, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db4a20198860, replyNumber=0, likeNumber=90, createdTime=2020-10-13, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db4a20198860, moduleTitle=Sci Rep：肌肉浸润性或转移性膀胱癌患者化疗的模式和临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db4a20198860)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386670, encodeId=ccf613866e03b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Oncologist：Nivolumab加低剂量Ipilimumab为既往治疗的微卫星不稳定及高/错配修复缺陷型转移性结直肠癌患者提供新的治疗选择, objectType=article, longId=201431, objectId=64b22014318f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64b22014318f, replyNumber=0, likeNumber=72, createdTime=2020-10-02, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64b22014318f, moduleTitle=Oncologist：Nivolumab加低剂量Ipilimumab为既往治疗的微卫星不稳定及高/错配修复缺陷型转移性结直肠癌患者提供新的治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64b22014318f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386669, encodeId=41ca1386669bf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：转移性去势抵抗性前列腺癌c-MET和雄激素受体双重阻断:恩扎鲁胺和克唑替尼联合应用的一期研究, objectType=article, longId=201364, objectId=cf922013647f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf922013647f, replyNumber=0, likeNumber=67, createdTime=2020-09-30, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf922013647f, moduleTitle=Clin Cancer Res：转移性去势抵抗性前列腺癌c-MET和雄激素受体双重阻断:恩扎鲁胺和克唑替尼联合应用的一期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf922013647f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386668, encodeId=fec31386668de, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle= Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌, objectType=article, longId=201131, objectId=a81a2011316b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a81a2011316b, replyNumber=0, likeNumber=81, createdTime=2020-09-25, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a81a2011316b, moduleTitle= Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a81a2011316b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386667, encodeId=f1c7138666ece, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：二代紫杉烷卡巴他赛治疗转移性胃癌的疗效, objectType=article, longId=200858, objectId=da7d20085840, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da7d20085840, replyNumber=0, likeNumber=83, createdTime=2020-09-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da7d20085840, moduleTitle=Clin Cancer Res：二代紫杉烷卡巴他赛治疗转移性胃癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da7d20085840)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386666, encodeId=d63b1386666ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=J Clin Oncol：恩扎鲁胺治疗转移性前列腺癌时18氟化钠PET/CT和循环肿瘤细胞的时空变化, objectType=article, longId=200818, objectId=cdcb20081831, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdcb20081831, replyNumber=0, likeNumber=68, createdTime=2020-09-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdcb20081831, moduleTitle=J Clin Oncol：恩扎鲁胺治疗转移性前列腺癌时18氟化钠PET/CT和循环肿瘤细胞的时空变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdcb20081831)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386665, encodeId=f0111386665c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet oncol：卡巴他赛治疗的转移性去势抵抗性前列腺癌患者的生活质量, objectType=article, longId=200700, objectId=cfcb200e0043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfcb200e0043, replyNumber=0, likeNumber=76, createdTime=2020-09-17, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfcb200e0043, moduleTitle=Lancet oncol：卡巴他赛治疗的转移性去势抵抗性前列腺癌患者的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfcb200e0043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386664, encodeId=c1731386664d0, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Cancer Res：阿帕他胺用于非转移性去势抵抗性前列腺癌的暴露-反应分析, objectType=article, longId=200657, objectId=46a120065e1f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46a120065e1f, replyNumber=0, likeNumber=65, createdTime=2020-09-15, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46a120065e1f, moduleTitle=Clin Cancer Res：阿帕他胺用于非转移性去势抵抗性前列腺癌的暴露-反应分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46a120065e1f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386663, encodeId=5ce71386663d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！, objectType=article, longId=200507, objectId=259720050e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=259720050e88, replyNumber=0, likeNumber=54, createdTime=2020-09-12, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=259720050e88, moduleTitle=NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=259720050e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386662, encodeId=a66f1386662ff, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌, objectType=article, longId=200381, objectId=9ed320038179, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed320038179, replyNumber=0, likeNumber=69, createdTime=2020-09-09, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed320038179, moduleTitle=FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ed320038179)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386661, encodeId=da4b138666123, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Glob Health：低成本的口服节律化疗治疗复发性转移性头颈癌, objectType=article, longId=200352, objectId=59bb200352df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59bb200352df, replyNumber=0, likeNumber=74, createdTime=2020-09-08, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59bb200352df, moduleTitle=Lancet Glob Health：低成本的口服节律化疗治疗复发性转移性头颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59bb200352df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386660, encodeId=a7f5138666002, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准, objectType=article, longId=200277, objectId=dacc2002e766, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dacc2002e766, replyNumber=0, likeNumber=68, createdTime=2020-09-06, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dacc2002e766, moduleTitle=NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dacc2002e766)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386659, encodeId=1a5d13866591a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, objectType=article, longId=200275, objectId=54442002e505, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54442002e505, replyNumber=0, likeNumber=65, createdTime=2020-09-06, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54442002e505, moduleTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54442002e505)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386658, encodeId=7b8913866583d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Cancer Cell :重大突破！吴家睿/曾嵘/张卫首次获得了转移性大肠癌的综合组学数据，为精准治疗奠定了基础, objectType=article, longId=200266, objectId=27de2002665e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27de2002665e, replyNumber=0, likeNumber=83, createdTime=2020-09-06, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27de2002665e, moduleTitle=Cancer Cell :重大突破！吴家睿/曾嵘/张卫首次获得了转移性大肠癌的综合组学数据，为精准治疗奠定了基础, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27de2002665e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386657, encodeId=1a0c138665e52, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关 , objectType=article, longId=200106, objectId=c2aa200106d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2aa200106d4, replyNumber=0, likeNumber=20, createdTime=2020-09-02, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2aa200106d4, moduleTitle=Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2aa200106d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA即将批准液体活检技术Parsortix用于转移性乳腺癌

2020-10-24

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗

2020-10-23

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Br J Cancer：FOLFOXIRI和贝伐单抗治疗转移性结直肠癌的临床研究汇总分析

2020-10-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Br J Cancer：错配修复不足的转移性结直肠癌dMMR mCRC患者的生存分析

2020-10-17

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JAMA Oncol ：咖啡又一功效！可改善结直肠癌晚期或转移性患者的生存率和恶化风险

2020-10-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Sci Rep：肌肉浸润性或转移性膀胱癌患者化疗的模式和临床结果

2020-10-13

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Oncologist：Nivolumab加低剂量Ipilimumab为既往治疗的微卫星不稳定及高/错配修复缺陷型转移性结直肠癌患者提供新的治疗选择

2020-10-02

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Cancer Res：转移性去势抵抗性前列腺癌c-MET和雄激素受体双重阻断:恩扎鲁胺和克唑替尼联合应用的一期研究

2020-09-30

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌

2020-09-25

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Cancer Res：二代紫杉烷卡巴他赛治疗转移性胃癌的疗效

2020-09-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

J Clin Oncol：恩扎鲁胺治疗转移性前列腺癌时18氟化钠PET/CT和循环肿瘤细胞的时空变化

2020-09-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet oncol：卡巴他赛治疗的转移性去势抵抗性前列腺癌患者的生活质量

2020-09-17

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Cancer Res：阿帕他胺用于非转移性去势抵抗性前列腺癌的暴露-反应分析

2020-09-15

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！

2020-09-12

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌

2020-09-09

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Glob Health：低成本的口服节律化疗治疗复发性转移性头颈癌

2020-09-08

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NERLYNX（neratinib）治疗HER2阳性转移性乳腺癌：将在加拿大获得批准

2020-09-06

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始

2020-09-06

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Cancer Cell :重大突破！吴家睿/曾嵘/张卫首次获得了转移性大肠癌的综合组学数据，为精准治疗奠定了基础

2020-09-06

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Eur Urol：继发于选择性成纤维细胞生长因子受体1-3抑制剂Infigratinib（BGJ398）的高磷血症与成纤维细胞生长因子受体3变异的晚期/转移性尿路癌的抗肿瘤疗效有关

2020-09-02

科室
- - 订阅+
  - 更多科室
工具
服务